Clinical Trials / Studies – Still Enrolling

Cancer

Canine Splenic Hemangiosarcoma

*NEW*  trial evaluating a novel immunotherapy protocol for canine splenic hemagniosarcoma.

Fully funded OTHER THAN SPLENECTOMY including pre-operative labwork and thoracic radiographs. Patient consult should ideally occur with Oncologist prior to splenectomy as tumor tissue must be collected using special procedures. However, it is possible for emergent informed consent to take place with slightly delayed tissue preparation for after-hours ER cases.

Please call Dr. Brenda Phillips 858-875-7500 or Dr Andi Flory 760-466-0600.  

Melanoma and Mast Cell Tumors

*NEW*  A funded clinical trial to evaluate a novel immunotherapy in dogs with melanoma and mast cell tumors

*NOTE*   Both trials are now fully enrolled.

 

 

Trial Specifics:

This trial is designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer.  An estimated 20 client-owned dogs with Melanoma or Mast Cell Tumors will be enrolled.  The antibody is administered IV by the study staff every 14 days for up to 10 treatments.  No placebo is used in this trial. Visits will be required every 2 weeks for a total trial period of 140 days. 

Trial Funding:

The trial is fully funded for the full trial duration (140 days), including the antibody and trial-related procedures.  

Trial Eligibility:

Dogs with one of the following cancers may be enrolled if they meet the specific criteria for each cancer:

Mast Cell Tumors - CLOSED - Fully enrolled

  • At least one measurable skin tumor +/- metastatic lymph node(s) > 2 cm
  • No intraabdominal metastasis
  • Prior therapy accepted with washout times to be discussed with the participating site

Melanoma - CLOSED - Fully enrolled

  • At least one measurable malignant tumor in the oral cavity, digit, skin +/- metastatic lymph node > 2 cm
  • No pulmonary metastasis
  • Prior therapy accepted with washout times to be discussed with site

 

For details please call Dr. Brenda Phillips at 858-875-7500. 

Canine Osteosarcoma 

This trial is now fully enrolled and closed. Canine osteosarcoma, fully funded trial evaluating a novel immunotherapy procedure. Either Sorrento Valley or San Marcos hospitals. A pre-amputation consult is required but a pre-consult histologic/cytologic diagnosis is not necessary.

--Please contact Dr. Brenda Phillips at 858-875-7500 or Dr. Andi Flory at 760-466-0600 for more information.

Dermatology

Clinical Trial for Atopic Dogs

*NEW* Dr. Laura Stokking is enrolling canine patients in a new clinical trial for atopic dogs. Patients cannot have had any long-acting treatments for allergy, such as glucocorticoid injections or Cytopoint. Food allergy should have been ruled out prior to enrollment.

--Please contact Drs. Laura Stokking or Wendy Terry at (858) 875-7500 for additional information. 

Emergency & Critical Care

Novel Rattlesnake Antivenom

*NEW* We are currently enrolling dogs that have been bitten (or suspected to have been bitten) by a rattlesnake for treatment with a novel antivenom. Enrolled dogs will receive free bloodwork on presentation (CBC, chemistry, coagulation panel) and trial antivenom at no cost to the client. Patients are required to return for a 24 hour post-antivenom administration recheck and free bloodwork (CBC, chemistry, coagulation panel). Owners must commit to the 24 hour recheck as well as use of their pet’s photos and/or videos for research and publication purposes. Patients are now being enrolled at Sorrento Valley, and North County enrollment begins August 14.

--Contact Dr. Erica O’Donnell or Nicole Edwards, RVT at (858) 875-7500. 

Internal Medicine

Canine Bile Acid Diarrhea and Microbial Dysbiosis Study

We are enrolling dogs with signs of inflammatory bowel disease, with or without histopathologic evidence, that are on current standard therapies (prednisone, diet) but continue to have diarrhea. A GI panel and fecal analysis for bile acid concertation and enteropathogens, along with a dysbiosis index will be performed through the GI Lab at Texas A&M. Dogs with a non-GI disease to explain their sign will be excluded. Patients will be randomly assigned into a placebo or cholestyramine group. Owners will be asked to grade their dog’s feces daily. Dogs will be re-evaluated at 3, 6, and 16 weeks post induction of therapies. At these rechecks, a fecal sample will be collected and submitted for a fecal bile acid analysis and microbial evaluation. All study related expenses will be funded. Cost to initial diagnosis of a chronic enteropathy will be covered by clients.

--Contact Drs. John Gil or Steve Hill at (858) 875-7500

Clinical Trial for Diabetic Dogs

VSH is participating in an exciting new clinical trial using a novel stem cell therapy to resolve diabetes mellitus in dogs! Dogs must weigh 5 to 12 kg, and be free of significant other systemic illnesses, on insulin (preferably Vetsulin), and at least partially controlled. Owners must be willing to perform glucose curves at home (with training), and to reliably bring the dog in for follow-up visits over 3 years. All study-associated costs are covered for the study duration (labs, procedures, insulin, glucometer, exams, etc.), including the initial screening visit, so we encourage any potential candidates to come in for formal screening with Drs. Loy Son, Gil, Dong, or Fischer.

--Visit website for additional details or call (858) 875-7500. 

Glucocorticoids and spec cPL study

Patients who will be started on glucocorticoids (minimum dose of 0.5mg/kg/day) and will need to be on them for at least 3 weeks. Patients will receive a spec cPL prior to administration of any glucocorticoids and at least 3 weeks after starting glucocorticoid therapy at no charge. Patients are being enrolled in North County and Sorrento Valley.

--Please call Drs. Sarah Cocker or Keith Richter at (858) 875-7500.

Surgery

Tarsal Replacement Surgery

*NEW* Clinical trial on tarsal replacement surgery.  Dogs greater than 30kg with end stage osteoarthritis of the Tarsus. 

--Contact Dr. Josh Jackson at (858) 875-7500 for details.